CA2261813A1 - Pharmaceutical composition containing a 5ht2c antagonist and a d2 antagonist - Google Patents

Pharmaceutical composition containing a 5ht2c antagonist and a d2 antagonist Download PDF

Info

Publication number
CA2261813A1
CA2261813A1 CA002261813A CA2261813A CA2261813A1 CA 2261813 A1 CA2261813 A1 CA 2261813A1 CA 002261813 A CA002261813 A CA 002261813A CA 2261813 A CA2261813 A CA 2261813A CA 2261813 A1 CA2261813 A1 CA 2261813A1
Authority
CA
Canada
Prior art keywords
antagonist
compound
pharmaceutically acceptable
5ht2c
antagonist activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002261813A
Other languages
English (en)
French (fr)
Inventor
Thomas Paul Blackburn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2261813A1 publication Critical patent/CA2261813A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002261813A 1996-07-26 1997-07-22 Pharmaceutical composition containing a 5ht2c antagonist and a d2 antagonist Abandoned CA2261813A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9615767.2 1996-07-26
GBGB9615767.2A GB9615767D0 (en) 1996-07-26 1996-07-26 Novel treatment
PCT/EP1997/004159 WO1998004289A2 (en) 1996-07-26 1997-07-22 Pharmaceutical composition containing a 5ht2c antagonist and a d2 antagonist

Publications (1)

Publication Number Publication Date
CA2261813A1 true CA2261813A1 (en) 1998-02-05

Family

ID=10797573

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002261813A Abandoned CA2261813A1 (en) 1996-07-26 1997-07-22 Pharmaceutical composition containing a 5ht2c antagonist and a d2 antagonist

Country Status (19)

Country Link
EP (1) EP0936924A2 (pt)
JP (1) JP2000516924A (pt)
KR (1) KR20000029564A (pt)
CN (1) CN1230894A (pt)
AR (1) AR008083A1 (pt)
AU (1) AU725817B2 (pt)
BR (1) BR9710568A (pt)
CA (1) CA2261813A1 (pt)
CO (1) CO5031292A1 (pt)
CZ (1) CZ23799A3 (pt)
GB (1) GB9615767D0 (pt)
HU (1) HUP9903619A3 (pt)
IL (1) IL128219A0 (pt)
NO (1) NO990322L (pt)
NZ (1) NZ333813A (pt)
PL (1) PL331426A1 (pt)
TR (1) TR199900140T2 (pt)
WO (1) WO1998004289A2 (pt)
ZA (1) ZA976593B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9612883D0 (en) * 1996-06-20 1996-08-21 Smithkline Beecham Plc Novel compounds
WO2000030649A1 (en) * 1998-11-23 2000-06-02 Sepracor Inc. Pharmaceutical compositions containing olanzapine-n-oxide
US6348455B1 (en) 1998-11-23 2002-02-19 Sepracor Inc. Desmetylolanzapine compositions and methods
JP2002530339A (ja) 1998-11-23 2002-09-17 セプラコール， インク． ２−ヒドロキシメチルオランザピン組成物及び方法
AU3757500A (en) 1999-03-18 2000-10-04 Childrens Hospital Research Foundation A method of treating bulimia nervosa and related eating disorders by administration of atypical antipsychotic medications
WO2000071106A2 (en) * 1999-05-19 2000-11-30 Astrazeneca Ab Method of treating weight gain
WO2005013969A1 (en) * 2003-07-15 2005-02-17 Janssen Pharmaceutica N.V. Antipsychotic agent with socializing properties

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9500998D0 (sv) * 1995-03-19 1995-03-19 Haakan Wilhelm Wikstroem New sulfone ester analogues of iso-clozapine and related structures: atypical neuroleptics

Also Published As

Publication number Publication date
ZA976593B (en) 1999-01-25
GB9615767D0 (en) 1996-09-04
AU4297297A (en) 1998-02-20
WO1998004289A3 (en) 1998-03-19
BR9710568A (pt) 1999-08-17
NZ333813A (en) 2000-07-28
KR20000029564A (ko) 2000-05-25
NO990322L (no) 1999-03-24
AU725817B2 (en) 2000-10-19
IL128219A0 (en) 1999-11-30
HUP9903619A2 (hu) 2000-10-28
PL331426A1 (en) 1999-07-19
CZ23799A3 (cs) 1999-06-16
WO1998004289A2 (en) 1998-02-05
CO5031292A1 (es) 2001-04-27
NO990322D0 (no) 1999-01-25
AR008083A1 (es) 1999-12-09
EP0936924A2 (en) 1999-08-25
JP2000516924A (ja) 2000-12-19
HUP9903619A3 (en) 2001-03-28
CN1230894A (zh) 1999-10-06
TR199900140T2 (xx) 1999-03-22

Similar Documents

Publication Publication Date Title
US6642228B1 (en) α1b-adrenergic receptor antagonists
US20040186102A1 (en) Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists
US20090023773A1 (en) Compositions and methods for modulating gated ion channels
US20070197509A1 (en) Compositions and methods for modulating gated ion channels
US20070099900A1 (en) Methods of modulating neurotrophin-mediated activity
SK10832002A3 (sk) Deriváty 1,3-dihydro-2H-indol-2-ónu, spôsob ich prípravy a farmaceutická kompozícia, ktorá ich obsahuje
JP2001518895A (ja) ソマトスタチン作働薬
JP2002535331A (ja) 新規血管形成阻害薬
JPH07291964A (ja) 新規ベンズイミダゾ−ルのピペリジン誘導体
JPH08253474A (ja) インドールピペリジン誘導体
JPH09502177A (ja) ５ｈｔ１ｄレセプター拮抗薬用インドールおよびインドリン誘導体
JPH09501171A (ja) ５ｈｔ１ｄ受容体アンタゴニストとしてのアミド誘導体
PT2252611E (pt) (di-hidro)pirrolo[2,1-a]isoquinolinas
JP2005525332A (ja) ５−ｈｔ６受容体アフィニティーを有するスルホニル化合物
WO1997008167A1 (en) 5ht2c and 5ht2b antagonists
IE51551B1 (en) Isoquinoline derivatives,process for their preparation and pharmaceutical formulations containing them and their use
CN111548345A (zh) 一类苯并咪唑类衍生物及其制备方法和应用
EP0912556B1 (en) Indoline derivatives useful as 5-ht-2c receptor antagonists
CA2261813A1 (en) Pharmaceutical composition containing a 5ht2c antagonist and a d2 antagonist
NO142838B (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive isokinolinderivater.
JP5062938B2 (ja) セロトニン受容体及びドーパミン受容体にアフィニティーを有する新規ｎ，ｎ’−二置換ベンゾイミダゾロン誘導体
TW382015B (en) Pyridin-3-yloxy-pyridin- or pyridazin-3-ylcarbamoyl-indoline derivatives having 5HT2c receptor antagonist activity, a process for the preparation thereof, and a pharmaceutical composition comprising them
JPH03218356A (ja) トランス―４―アミノ（アルキル）―１―ピリジルカルバモイルシクロヘキサン化合物およびその医薬用途
NO143744B (no) Analogifremgangsmaate for fremstilling av fysiologisk aktive benz(de)isokinolin-derivater
US6159941A (en) Use of somatostatin agonists and antagonists for treating diseases related to the eye

Legal Events

Date Code Title Description
FZDE Discontinued